Prab: CSV import

2025-02-17T02:08:16Z

CSV import

← Older revision		Revision as of 02:08, 17 February 2025
Line 16:		Line 16:
	{{antiviral agents}}		{{antiviral agents}}
	{{coststubd}}		{{coststubd}}
			<gallery>
			File:Maraviroc.svg\|Chemical structure of Maraviroc
			File:Maraviroc_molecule_ball.png\|Ball-and-stick model of Maraviroc
			</gallery>

Prab: Created page with " {{intro}} Maraviroc is a chemokine co-receptor 5 (CCR5) antagonist, the first of a new class of agents active against the human immunodeficiency virus (HIV) and the acqui..."

2019-05-01T09:14:02Z

Created page with " {{intro}} Maraviroc is a chemokine co-receptor 5 (CCR5) antagonist, the first of a new class of agents active against the human immunodeficiency virus (HIV) and the acqui..."

New page

{{intro}}
Maraviroc is a chemokine co-receptor 5 (CCR5) antagonist, the first of a new class of agents active against the human immunodeficiency virus ([[HIV]]) and the acquired immunodeficiency syndrome ([[AIDS]]).

{{fda}}
{{PAGENAME}} was approved for use in the United States in 2007 and has had limited use.

{{livtox}}
Maraviroc has been associated with elevations in serum [[aminotransferase]] levels and to several cases of acute, clinically apparent [[liver injury]].

{{moa}}
Maraviroc (mar" a vir' ok) is relatively new antiretroviral drug that targets one of the receptors for [[HIV]] that is present on the surface of lymphocytes. Maraviroc interrupts the binding of [[HIV]] to target cells by blocking the chemokine coreceptor 5 (CCR5), a necessary receptor in the uptake of [[HIV]] into cells. Maraviroc has both in vitro and in vivo activity against [[HIV]] and several randomized controlled trials have shown that it leads to significant decline in [[HIV]] RNA levels and rises in peripheral [[CD4 T cell counts]. Maraviroc was given accelerated approval for use in [[HIV]] infection in the United States in 2007 and is currently used in a relatively small proportion of antiretroviral regimens, being recommended largely for [[HIV]]-treatment experienced adult patients with CCR5-tropic strains of [[HIV]].

{{dose}}
Maraviroc is available as 150 and 300 mg tablets under the brand name Selzentry. The recommended dose is 150 to 600 mg twice daily in combination with other classes of antiretroviral agents. Common side effects include cough, [[fever]], [[rash]] and [[dizziness]].
{{antiviral agents}}
{{coststubd}}

Maraviroc - Revision history

Prab: CSV import

Prab: Created page with " {{intro}} Maraviroc is a chemokine co-receptor 5 (CCR5) antagonist, the first of a new class of agents active against the human immunodeficiency virus (HIV) and the acqui..."